380 INTERLOCKEN CRESCENT SUITE 780 BROOMFIELD, CO 80021 Get Directions
380 INTERLOCKEN CRESCENT SUITE 780 BROOMFIELD, CO 80021 Get Directions
Accera discovers and develops breakthroughs in treating central nervous system disorders, focusing on serious and difficult-to-diagnose neurodegenerative diseases for which there are no simple tests, no cures and a lack of new, innovative treatments to improve quality of life for patients and their families. The company is pioneering unique scientific approaches to treating CNS disorders, through products with novel mechanisms-of-action that target the underlying factors giving rise to symptoms.
Currently our product pipeline includes therapeutic treatments for Parkinson's disease, Alzheimer's disease and other age-related memory loss disorders. These products are in advanced clinical development where they have demonstrated significant efficacy and outstanding safety compared to approved drugs in the marketplace.
Through our proprietary scientific platform, Accera is developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. Based on our proprietary platform, our first product for Alzheimer's (Axona) targets metabolic defects in brain neurons.
As an industry innovator, Accera's new and novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated treatments, and their families. We are committed to improving the care and quality of life of patients.
© Dun & Bradstreet, Inc. 2024. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.